Recordati (REC) ICR Healthcare's 12th Annual Healthcare Conference summary

Keynote interview: Leadership and strategy in rare disease pharma

• Transition to non-family leadership brought cultural change, empowering teams and increasing transparency.

• Focus on international expansion, especially in the U.S., with rare disease as the fastest-growing segment.

• Rare disease business is nearing 40% of revenues and expected to reach parity with traditional business soon.

• Acquisition strategy targets products with unmet medical needs and strong return on capital, with recent deals to expand the pipeline.

• U.S. market remains central due to higher profitability and opportunity, with minimal expected impact from political changes.

Panel: Strategic options for biotech exits and financing

• Biotech companies must balance licensing, M&A, IPO, and private financing, often running parallel processes.

• Board and investor alignment is critical, as some seek quick exits while others prefer long-term value creation.

• Licensing deals with low upfronts and high backend milestones are risky due to loss of control and uncertain payouts.

• IPOs provide optionality but require readiness and can be risky if market conditions change; dual-track processes are common.

• Trade sales offer clean exits but may not satisfy all shareholders; bridge financing and spin-outs are considered to maximize value.

Market outlook and investor sentiment

• 2025 is expected to be volatile but offers opportunities for agile companies, especially as larger firms exit certain fields.

• Investor focus remains on management quality, science, and hot therapeutic areas like cardiovascular, radiopharma, and neurology.

• Shareholder activism is increasing, with investors demanding more engagement and influence over company strategy.

• Optimism about the IPO market for 2025 is high, with several successful recent offerings and strong investor appetite.

• Companies are advised to maintain flexibility, pursue multiple strategic options, and prioritize value creation for all stakeholders.